Enabling Biologic Drug Delivery Of Volumes Beyond 1 mL
By Megan Lan and Patrick Le Gal

Patients affected by chronic diseases commonly require regular injections of biologics, and many opt for self-injection. However, a wide range of biologics used to treat chronic diseases are now developed in volumes higher than 1 mL, requiring changes to the self-injection devices previously available. As the biological drug design space evolves toward formulations with larger dose volume and higher viscosity, the device industry is adapting by developing more innovative delivery systems.
To accommodate these advances, delivery system manufacturers need to use methodologies and tools to manage conflicting requirements and to offer delivery solutions that balance performance, robustness, and usability while delivering higher volume or viscosity biologics. To support delivery of advanced biologics, BD offers safety systems, such as BD UltraSafeTM 2.25 mL passive needle guard, providing acceptable trade-offs to meet patient’s needs, such as easy-to-use, comfortable, and safe for its intended use.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.